Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Neoplasms of the CNS

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 73 articles: HTML format

Single Articles

October 2026
1. PADEVIT L, Weiss T, Vasella F, Neidert MC, et al
   Neurodevelopmental Blueprint in Gliomas: Toward an Ontogenetic Multimodal Integrated Therapy.
   J Clin Oncol. 2026 Oct 14:JCO2502798. doi: 10.1200/JCO-25-02798.
   PubMed     Abstract available
   
   
   September 2026
2. WEINBERG JS, Imber BS, DiNapoli V, Moss NS, et al
   Surgery and tile-based radiation therapy versus surgery and stereotactic radiation for newly diagnosed brain metastases (ROADS): a randomized, open-label, phase 3 trial.
   J Clin Oncol. 2026 Sep 28:101200JCO2601894. doi: 10.1200/JCO-26-01894.
   PubMed     Abstract available
   
   
   August 2026
3. LEUTHARDT EC, Chiang V, Hadjipanayis CG, Landazuri P, et al
   Laser Interstitial Thermal Therapy for Brain Tumors: A Prospective Multicenter Analysis of Patients From the LAANTERN Study.
   J Clin Oncol. 2026 Aug 17:JCO2502604. doi: 10.1200/JCO-25-02604.
   PubMed     Abstract available
   
   
   
4. KINSLOW CJ, Minniti G, Brown PD, Vogelbaum MA, et al
   Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas.
   J Clin Oncol. 2026 Aug 12:JCO2501846. doi: 10.1200/JCO-25-01846.
   PubMed     Abstract available
   
   
   July 2026
5. LIANG B, Weil M
   Corticosteroids in Glioblastoma Management: A Reconsideration of a 65-Year Practice.
   J Clin Oncol. 2026 Jul 22:JCO2600191. doi: 10.1200/JCO-26-00191.
   PubMed    
   
   
   
6. NABORS LB, Lobbous M, Han X, Fiveash J, et al
   Intracranial Injection of Investigational Ex Vivo Expanded and Activated Gamma-Delta T Cells Engineered With a Methylguanine-DNA Methyltransferase-Expressing Lentivector in Patients With Primary Glioblastoma.
   J Clin Oncol. 2026 Jul 8:JCO2502463. doi: 10.1200/JCO-25-02463.
   PubMed     Abstract available
   
   
   
7. MARCISCANO AE, Shih HA
   Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.
   J Clin Oncol. 2026 Jul 2:JCO2600771. doi: 10.1200/JCO-26-00771.
   PubMed    
   
   
   
8. BAUMERT BG, Hegi ME, van den Bent MJ, von Deimling A, et al
   Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).
   J Clin Oncol. 2026 Jul 2:JCO2502735. doi: 10.1200/JCO-25-02735.
   PubMed     Abstract available
   
   
   June 2026
9. WILSON MR, Lewis KL, Kirkwood AA, Cwynarski K, et al
   High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.
   J Clin Oncol. 2026 Jun 11:JCO2600947. doi: 10.1200/JCO-26-00947.
   PubMed     Abstract available
   
   
   May 2026
10. KOTECHA R, Polley MY, Vogelbaum MA, Perry A, et al
    Long-Term Analysis of NRG Oncology RTOG 0539: A Phase II Trial of Observation for Low-Risk Meningioma and Radiotherapy for Intermediate- and High-Risk Meningioma.
    J Clin Oncol. 2026 May 27:JCO2501441. doi: 10.1200/JCO-25-01441.
    PubMed     Abstract available
    
    
    
11. RUDRA GUPTA T, Polley MC, Redd R, Lee EQ, et al
    Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.
    J Clin Oncol. 2026 May 22:JCO2501586. doi: 10.1200/JCO-25-01586.
    PubMed     Abstract available
    
    
    
12. LU S, Jia J, Ren K, Jia W, et al
    Multicenter Cohort Study of Original or Substitute Systemic Therapy With or Without Brain Radiotherapy for Extensive-Stage Small Cell Lung Cancer With Brain-Only Progression After First-Line Treatment.
    J Clin Oncol. 2026 May 14:JCO2502536. doi: 10.1200/JCO-25-02536.
    PubMed     Abstract available
    
    
    
13. HANSFORD JR, Manoharan N, Khan S, Chon R, et al
    Balancing Risk, Benefit, and Reality: Navigating Early Phase Studies in Pediatric Diffuse Midline Glioma.
    J Clin Oncol. 2026 May 12:JCO2600461. doi: 10.1200/JCO-26-00461.
    PubMed    
    
    
    
14. BALLMAN KV
    Lessons From GBM AGILE's Regorafenib Experience in Newly Diagnosed and Recurrent Glioblastoma.
    J Clin Oncol. 2026 May 12:JCO2600444. doi: 10.1200/JCO-26-00444.
    PubMed    
    
    
    
15. WEN PY, Berry DA, Buxton MB, Colman H, et al
    Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
    J Clin Oncol. 2026 May 7:JCO2601027. doi: 10.1200/JCO-26-01027.
    PubMed    
    
    
    April 2026
16. WEN PY, Berry DA, Buxton MB, Colman H, et al
    Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
    J Clin Oncol. 2026 Apr 14:JCO2501137. doi: 10.1200/JCO-25-01137.
    PubMed     Abstract available
    
    
    March 2026
17. COLMAN H, Lombardi G, Wong ET, Walbert T, et al
    STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.
    J Clin Oncol. 2026;44:641-652.
    PubMed     Abstract available
    
    
    
18. LI T, Zhou T, Wang B, Tao Z, et al
    Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study).
    J Clin Oncol. 2026 Mar 4:JCO2502021. doi: 10.1200/JCO-25-02021.
    PubMed     Abstract available
    
    
    January 2026
19. RUSTHOVEN CG, Serizawa T, Yamamoto M
    Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trials.
    J Clin Oncol. 2026 Jan 20:JCO2501794. doi: 10.1200/JCO-25-01794.
    PubMed    
    
    
    
20. NOGUCHI M, Nimura K, Koide Y
    Expanding Indications for Stereotactic Radiosurgery in Small Cell Lung Cancer With Brain Metastases.
    J Clin Oncol. 2026 Jan 20:JCO2501867. doi: 10.1200/JCO-25-01867.
    PubMed    
    
    
    
21. AKDOGAN O, Canaslan K, Hamitoglu B, Yazici O, et al
    Limitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastases.
    J Clin Oncol. 2026 Jan 20:JCO2501729. doi: 10.1200/JCO-25-01729.
    PubMed    
    
    
    
22. AIZER AA, Catalano PJ, Rahman R
    Reply to: "Limitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastases," "Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trials,"
    J Clin Oncol. 2026 Jan 20:JCO2502528. doi: 10.1200/JCO-25-02528.
    PubMed    
    
    
    August 2025
23. HUANG J
    Baseline Brain Metastasis Imbalance in TRUST: Implications for Interpreting Intracranial Efficacy of Taletrectinib.
    J Clin Oncol. 2025 Aug 21:JCO2500967. doi: 10.1200/JCO-25-00967.
    PubMed    
    
    
    
24. PEROL M, Li W, Lai RK, Zhou C, et al
    Reply to: "Baseline Brain Metastasis Imbalance in TRUST: Implications for Interpreting Intracranial Efficacy of Taletrectinib" and "Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer: Promising Yet Premature?".
    J Clin Oncol. 2025 Aug 21:JCO2501448. doi: 10.1200/JCO-25-01448.
    PubMed    
    
    
    
25. COOPER BT, Kondziolka D
    Modern Targeted Radiation in Patients With Brain Metastases From Small Cell Lung Cancer.
    J Clin Oncol. 2025 Aug 12:JCO2501259. doi: 10.1200/JCO-25-01259.
    PubMed    
    
    
    
26. GONDI V, Pugh SL, Mehta MP, Wefel JS, et al
    Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003.
    J Clin Oncol. 2025 Aug 11:JCO2500221. doi: 10.1200/JCO-25-00221.
    PubMed     Abstract available
    
    
    
27. LASSMAN AB, Polley MC, Iwamoto FM, Sloan AE, et al
    Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.
    J Clin Oncol. 2025 Aug 8:JCO2500618. doi: 10.1200/JCO-25-00618.
    PubMed     Abstract available
    
    
    July 2025
28. AIZER AA, Tanguturi SK, Shi DD, Catalano PJ, et al
    Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial.
    J Clin Oncol. 2025 Jul 11:JCO2500056. doi: 10.1200/JCO-25-00056.
    PubMed     Abstract available
    
    
    June 2025
29. BLAKELEY J, Mohile NA, Messersmith H, Lassman AB, et al
    Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2025;43:2129-2133.
    PubMed     Abstract available
    
    
    April 2025
30. SPERDUTO PW, Marqueen KE, Chang E, Li J, et al
    Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment.
    J Clin Oncol. 2025 Apr 17:JCO2401351. doi: 10.1200/JCO-24-01351.
    PubMed     Abstract available
    
    
    March 2025
31. WEISS SA, Djureinovic D, Wei W, Tran T, et al
    Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.
    J Clin Oncol. 2025 Mar 6:JCO2402219. doi: 10.1200/JCO-24-02219.
    PubMed     Abstract available
    
    
    January 2025
32. KACIMI SEO, Dehais C, Feuvret L, Chinot O, et al
    Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.
    J Clin Oncol. 2025;43:329-338.
    PubMed     Abstract available
    
    
    
33. HUANG RY, Youssef G, Nelson T, Wen PY, et al
    Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204.
    J Clin Oncol. 2025 Jan 3:JCO2400953. doi: 10.1200/JCO.24.00953.
    PubMed     Abstract available
    
    
    November 2024
34. NOGUCHI M, Shindo Y, Wakabayashi K, Koide Y, et al
    Significance of Up-Front Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Patients With Brain Metastases in the Era of New Generation Tyrosine Kinase Inhibitors.
    J Clin Oncol. 2024 Nov 15:JCO2401876. doi: 10.1200/JCO-24-01876.
    PubMed    
    
    
    
35. RUSTHOVEN CG, Miao E, Boe LA, Pike LRG, et al
    Reply to: Significance of Up-Front Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Patients With Brain Metastases in the Era of New Generation Tyrosine Kinase Inhibitors.
    J Clin Oncol. 2024 Nov 15:JCO2402129. doi: 10.1200/JCO-24-02129.
    PubMed    
    
    
    October 2024
36. 
    Erratum: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguan
    J Clin Oncol. 2024 Oct 10:JCO2402040. doi: 10.1200/JCO-24-02040.
    PubMed    
    
    
    September 2024
37. FORST DA, Podgurski AF, Strander SM, Whitman JD, et al
    NeuroCARE: A Randomized Controlled Trial of a Psychological Intervention for Caregivers of Patients With Primary Malignant Brain Tumors.
    J Clin Oncol. 2024 Sep 16:JCO2400065. doi: 10.1200/JCO.24.00065.
    PubMed     Abstract available
    
    
    August 2024
38. DOWLATI A, Hummel HD, Champiat S, Olmedo ME, et al
    Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update.
    J Clin Oncol. 2024 Aug 29:JCO2400553. doi: 10.1200/JCO.24.00553.
    PubMed     Abstract available
    
    
    
39. JENG MY, Yu HA
    Leptomeningeal Metastasis in the Era of CNS-Penetrant Tyrosine Kinase Inhibitor Therapy.
    J Clin Oncol. 2024;42:2727-2730.
    PubMed    
    
    
    
40. LIN FY, Stuckert A, Tat C, White M, et al
    Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.
    J Clin Oncol. 2024;42:2769-2779.
    PubMed     Abstract available
    
    
    July 2024
41. PIKE LRG, Miao E, Boe LA, Patil T, et al
    Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC).
    J Clin Oncol. 2024 Jul 24:JCO2302668. doi: 10.1200/JCO.23.02668.
    PubMed     Abstract available
    
    
    June 2024
42. YU Y, Miao E, Pike LRG
    Improved CNS Control With the Addition of Chemotherapy to Osimertinib: A Devil's Bargain?
    J Clin Oncol. 2024;42:2107-2108.
    PubMed    
    
    
    
43. KOTECHA R, Schiff D, Chakravarti A, Fleming JL, et al
    Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era.
    J Clin Oncol. 2024 Jun 4:JCO2302195. doi: 10.1200/JCO.23.02195.
    PubMed     Abstract available
    
    
    
44. PEROL M, Solomon BJ, Goto K, Park K, et al
    CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung Cancer.
    J Clin Oncol. 2024 Jun 3:JCO2400724. doi: 10.1200/JCO.24.00724.
    PubMed     Abstract available
    
    
    
45. PARK S, Baldry R, Jung HA, Sun JM, et al
    Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM).
    J Clin Oncol. 2024 Jun 3:JCO2400708. doi: 10.1200/JCO.24.00708.
    PubMed     Abstract available
    
    
    
46. MIKOLAJEWICZ N, Yee PP, Bhanja D, Trifoi M, et al
    Systematic Review of Cerebrospinal Fluid Biomarker Discovery in Neuro-Oncology: A Roadmap to Standardization and Clinical Application.
    J Clin Oncol. 2024;42:1961-1974.
    PubMed     Abstract available
    
    
    March 2024
47. XIAO H, Vaidya R, Hershman DL, Unger JM, et al
    Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022.
    J Clin Oncol. 2024 Mar 27:JCO2301777. doi: 10.1200/JCO.23.01777.
    PubMed     Abstract available
    
    
    February 2024
48. MARGOL AS, Molinaro AM, Onar-Thomas A, Resnick A, et al
    Use of External Control Cohorts in Pediatric Brain Tumor Clinical Trials.
    J Clin Oncol. 2024 Feb 23:JCO2301084. doi: 10.1200/JCO.23.01084.
    PubMed     Abstract available
    
    
    
49. WU J, Heidelberg RE, Gajjar A
    Adolescents and Young Adults With Cancer: CNS Tumors.
    J Clin Oncol. 2024;42:686-695.
    PubMed     Abstract available
    
    
    
50. ARRILLAGA-ROMANY I, Gardner SL, Odia Y, Aguilera D, et al
    ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
    J Clin Oncol. 2024 Feb 9:JCO2301134. doi: 10.1200/JCO.23.01134.
    PubMed     Abstract available
    
    
    December 2023
51. DE VIS JB, Cmelak AJ, Osmundson EC
    Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy?
    J Clin Oncol. 2023 Dec 11:JCO2302151. doi: 10.1200/JCO.23.02151.
    PubMed    
    
    
    
52. LEHRER EJ, Trifiletti DM, Fadul CE, Brown PD, et al
    Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: A Reason for Optimism While Avoiding Overreaching Interpretations.
    J Clin Oncol. 2023 Dec 11:JCO2301876. doi: 10.1200/JCO.23.01876.
    PubMed    
    
    
    
53. JANNE PA, Planchard D, Kobayashi K, Cheng Y, et al
    CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Dec 2:JCO2302219. doi: 10.1200/JCO.23.02219.
    PubMed     Abstract available
    
    
    November 2023
54. HAAS-KOGAN DA, Aboian MS, Minturn JE, Leary SES, et al
    Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial.
    J Clin Oncol. 2023 Nov 17:JCO2301838. doi: 10.1200/JCO.23.01838.
    PubMed     Abstract available
    
    
    
55. RUDIN CM, Liu SV, Soo RA, Lu S, et al
    SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Nov 17:JCO2301363. doi: 10.1200/JCO.23.01363.
    PubMed     Abstract available
    
    
    
56. FRIEDMAN HS, Prados MD, Wen PY, Mikkelsen T, et al
    Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma.
    J Clin Oncol. 2023;41:4945-4952.
    PubMed     Abstract available
    
    
    
57. MELLINGHOFF IK
    Flashback Foreword: Bevacizumab and Irinotecan in Recurrent Glioblastoma.
    J Clin Oncol. 2023;41:4943-4944.
    PubMed    
    
    
    October 2023
58. LEWIS KL, Jakobsen LH, Villa D, Smedby KE, et al
    High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.
    J Clin Oncol. 2023 Oct 5:JCO2300365. doi: 10.1200/JCO.23.00365.
    PubMed     Abstract available
    
    
    September 2023
59. WEN PY, van den Bent M, Youssef G, Cloughesy TF, et al
    RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
    J Clin Oncol. 2023 Sep 29:JCO2301059. doi: 10.1200/JCO.23.01059.
    PubMed     Abstract available
    
    
    
60. BANU MA, McKhann GM
    Maximizing Extent of Resection for Noneloquent Glioblastoma: Fluorescent Dye or Intraoperative Magnetic Resonance Imaging?
    J Clin Oncol. 2023 Sep 18:JCO2300963. doi: 10.1200/JCO.23.00963.
    PubMed    
    
    
    
61. RAHMAN R, Trippa L, Lee EQ, Arrillaga-Romany I, et al
    Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization.
    J Clin Oncol. 2023 Sep 18:JCO2300493. doi: 10.1200/JCO.23.00493.
    PubMed     Abstract available
    
    
    August 2023
62. HARGRAVE DR, Terashima K, Hara J, Kordes UR, et al
    Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma.
    J Clin Oncol. 2023 Aug 29:JCO2300558. doi: 10.1200/JCO.23.00558.
    PubMed     Abstract available
    
    
    
63. LU BY, Goldberg SB
    Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy?
    J Clin Oncol. 2023 Aug 21:JCO2301323. doi: 10.1200/JCO.23.01323.
    PubMed    
    
    
    
64. NADAL E, Rodriguez-Abreu D, Simo M, Massuti B, et al
    Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).
    J Clin Oncol. 2023 Aug 21:JCO2202561. doi: 10.1200/JCO.22.02561.
    PubMed     Abstract available
    
    
    June 2023
65. RODER C, Stummer W, Coburger J, Scherer M, et al
    Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial.
    J Clin Oncol. 2023 Jun 19:JCO2201862. doi: 10.1200/JCO.22.01862.
    PubMed     Abstract available
    
    
    
66. NEGRAO MV, Spira AI, Heist RS, Janne PA, et al
    Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS(G12C)-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases.
    J Clin Oncol. 2023 Jun 16:JCO2300046. doi: 10.1200/JCO.23.00046.
    PubMed     Abstract available
    
    
    
67. DUMMER R, Corrie P, Gutzmer R, Meniawy TM, et al
    First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
    J Clin Oncol. 2023 Jun 12:JCO2202199. doi: 10.1200/JCO.22.02199.
    PubMed     Abstract available
    
    
    May 2023
68. WARREN KE, Vezina G, Krailo M, Springer L, et al
    Phase II Randomized Trial of Lenalidomide in Children With Pilocytic Astrocytomas and Optic Pathway Gliomas: A Report From the Children's Oncology Group.
    J Clin Oncol. 2023 May 1:JCO2201777. doi: 10.1200/JCO.22.01777.
    PubMed     Abstract available
    
    
    April 2023
69. HSU TW, Liang CS, Tsai SJ, Bai YM, et al
    Risk of Major Psychiatric Disorders Among Children and Adolescents Surviving Malignancies: A Nationwide Longitudinal Study.
    J Clin Oncol. 2023;41:2054-2066.
    PubMed     Abstract available
    
    
    
70. YOUSSEF G, Rahman R, Bay C, Wang W, et al
    Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma.
    J Clin Oncol. 2023 Apr 7:JCO2201579. doi: 10.1200/JCO.22.01579.
    PubMed     Abstract available
    
    
    March 2023
71. MUTTER JA, Alig SK, Esfahani MS, Lauer EM, et al
    Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas.
    J Clin Oncol. 2023;41:1684-1694.
    PubMed     Abstract available
    
    
    February 2023
72. DIEZ VALLE R
    Long-Term Outcomes in Resected IDH-Mutant Subtypes of Diffuse Low-Grade Glioma.
    J Clin Oncol. 2023 Feb 28:JCO2202428. doi: 10.1200/JCO.22.02428.
    PubMed    
    
    
    January 2023
73. GROMMES C
    Circulating Tumor DNA in the Blood: A New Frontier in Primary CNS Lymphoma?
    J Clin Oncol. 2023 Jan 20:JCO2202605. doi: 10.1200/JCO.22.02605.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum